Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Goodwill & Intangibles (2019 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Goodwill & Intangibles for 7 consecutive years, with $26.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill & Intangibles changed N/A year-over-year to $26.8 million, compared with a TTM value of $26.8 million through Sep 2025, changed N/A, and an annual FY2024 reading of $27.4 million, up 57.63% over the prior year.
  • Goodwill & Intangibles was $26.8 million for Q3 2025 at X4 Pharmaceuticals, down from $27.0 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $27.4 million in Q4 2024 and bottomed at $17.4 million in Q4 2021.
  • Average Goodwill & Intangibles over 5 years is $21.0 million, with a median of $17.4 million recorded in 2021.
  • The sharpest move saw Goodwill & Intangibles tumbled 36.0% in 2021, then soared 57.63% in 2024.
  • Year by year, Goodwill & Intangibles stood at $17.4 million in 2021, then changed by 0.0% to $17.4 million in 2022, then changed by 0.0% to $17.4 million in 2023, then skyrocketed by 57.63% to $27.4 million in 2024, then dropped by 2.05% to $26.8 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for XFOR at $26.8 million in Q3 2025, $27.0 million in Q2 2025, and $27.4 million in Q4 2024.